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Abstract
Background: High dietary fructose has structural and metabolic cardiac impact, but the potential for fructose to exert direct
myocardial action is uncertain. Cardiomyocyte functional responsiveness to fructose, and capacity to transport fructose has
not been previously demonstrated.
Objective: The aim of the present study was to seek evidence of fructose-induced modulation of cardiomyocyte excitation-
contraction coupling in an acute, in vitro setting.
Methods and Results: The functional effects of fructose on isolated adult rat cardiomyocyte contractility and Ca
2+ handling
were evaluated under physiological conditions (37uC, 2 mM Ca
2+, HEPES buffer, 4 Hz stimulation) using video edge
detection and microfluorimetry (Fura2) methods. Compared with control glucose (11 mM) superfusate, 2-deoxyglucose
(2 DG, 11 mM) substitution prolonged both the contraction and relaxation phases of the twitch (by 16 and 36%
respectively, p,0.05) and this effect was completely abrogated with fructose supplementation (11 mM). Similarly, fructose
prevented the Ca
2+ transient delay induced by exposure to 2 DG (time to peak Ca
2+ transient: 2 DG: 29.062.1 ms vs.
glucose: 23.661.1 ms vs. fructose +2 DG: 23.761.0 ms; p,0.05). The presence of the fructose transporter, GLUT5 (Slc2a5)
was demonstrated in ventricular cardiomyocytes using real time RT-PCR and this was confirmed by conventional RT-PCR.
Conclusion: This is the first demonstration of an acute influence of fructose on cardiomyocyte excitation-contraction
coupling. The findings indicate cardiomyocyte capacity to transport and functionally utilize exogenously supplied fructose.
This study provides the impetus for future research directed towards characterizing myocardial fructose metabolism and
understanding how long term high fructose intake may contribute to modulating cardiac function.
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Introduction
Evidence is emerging that high dietary fructose has structural
and metabolic impact on the myocardium [1,2,3]. The extent to
which myocardial cellular alterations reflect direct or indirect
actions of elevated fructose intake is not known. Cellular fructose
uptake and metabolism is most well described in hepatocytes [4,5]
and there is some evidence to suggest that skeletal muscle also has
the capacity to utilize fructose [6]. Whether cardiomyocytes can
similarly utilize fructose as a functional substrate has not been
determined.
Cellular fructose uptake is mediated by insulin-independent
transporters. Fructose is rapidly phosphorylated by fructokinase
and bypasses the glycolytic rate-limiting enzyme, phosphofructo-
kinase, proceeding through glycolysis to produce pyruvate and
lactate in a less-controlled manner than glucose [7]. Thus, high
throughput fructose may be associated with altered cellular
glycolytic regulation. Basal plasma fructose concentrations are
low (postprandial fructose ,8–20 mM, human) but with elevated
plasma fructose non-hepatic tissue metabolism of fructose may
become significant [8].
The myocardial capacity for fructose metabolism is not well
characterized, but some evidence suggests that fructose metabo-
lism proceeds in cardiac tissue. The expression and activity of
fructokinase has been detected in heart tissue [9,10] and fructose-
mediated myocardial lactate production has been reported [11].
Furthermore, cardiac fructokinase (ketohexokinase) gene expres-
sion is upregulated in diabetic mice [10]. Cardiomyocyte capacity
for fructose uptake has not been defined. In humans and rodents
the circulating fructose concentration is significantly lower than
glucose. Thus, fructose uptake by transporters which mediate
fructose and glucose entry competitively (e.g. GLUT11 and
GLUT12 transporters [12,13]), would be unlikely to occur in vivo.
In contrast, GLUT5 has low affinity for glucose and could be a
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25204good candidate for a functional fructose transporter in the heart.
However, cardiac GLUT5 expression and functional evidence of
cardiomyocyte fructose uptake has not yet been reported.
Cardiomyocyte Ca
2+ management is key to ensuring electro-
mechanical functionality and stability. Although fatty acid
oxidation supplies the majority of cardiomyocyte ATP production,
there is evidence that ATP produced by glycolysis has a significant
role in Ca
2+ handling. The close association of glycolytic enzymes
with Ca
2+ transporters provides indication that specific cardiac
excitation-contraction coupling processes are particularly reliant
on glycolytically produced ATP [14]. Fructose-derived ATP
generated through glycolysis could potentially support components
of excitation-contraction coupling Ca
2+ transport, but a role for
fructose in direct cardiomyocyte functional modulation has not yet
been demonstrated.
The aim of the present study was to seek evidence of fructose-
induced modulation of cardiomyocyte excitation-contraction
coupling in an acute, in vitro setting. Effect of fructose influence
on cardiomyocyte function and Ca
2+ handling was evaluated using
isolated adult rat cardiomyocytes. Molecular evidence of expres-
sion of the fructose transporter GLUT5 was sought in both
ventricular tissue and in cardiomyocytes. This is the first study to
identify that fructose has direct action on cardiomyocyte
contractile performance, and that cardiomyocytes express the
fructose-specific GLUT5 transporter.
Materials and Methods
Ethical approval
This study was carried out in compliance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health and the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes.
All experiments were approved by the Animal Ethics Committee
at the University of Melbourne (#0703281).
Adult rat cardiomyocyte isolation
Ventricular cardiomyocytes were isolated from adult male
Sprague Dawley rats. Briefly, rats were decapitated under deep
isoflurane anaesthesia and hearts were excised and retrogradely
perfused with bicarbonate-buffered Ca
2+-free Krebs (in mM: 118
NaCl, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO47H2O, 25 NaHCO3,1 1
glucose) followed by addition of Type II Collagenase (0.56 mg/ml,
295 U/mg, Worthington Biochemical Corporation, NJ, USA) for
heart digestion. Left ventricular cells were dispersed in bicarbon-
ate-buffered Krebs solution with 0.25 mM CaCl2 and 26 mg/ml
trypsin inhibitor [15].
Myocyte twitch and Ca
2+ transient measurements
Cardiomyocytes were field stimulated at 4 Hz and superfused at
37uC with a HEPES-Krebs buffer (in mM: 146.2 NaCl, 4.69 KCl,
0.35 NaH2PO4H2O, 1.05 MgSO47H2O, 10 HEPES, 2 CaCl2)
supplemented with energy substrate/inhibitor as described below.
Cardiomyocyte twitch properties were assessed by video-based
edge detection (IonOptix, Milton, MA, USA). The indices used to
describe the twitch cycle (depicted in Figure 1A) were peak
shortening amplitude (PS, mm), peak shortening normalized to
diastolic cell length (% PS), area of the shortening phase (AS,
mm*ms), area of the lengthening phase (AL, mm*ms) and area of
the total twitch cycle (AT=A S+AL, mm*ms). Area values were
determined between baseline and cell length and were normalized
to peak shortening amplitude (AS/PS, AL/PS, AT/PS; mm*ms/
mm) in order to compare the relative periods of the shortening and
relaxation phases in different myocytes [16]. Maximum rates of
cardiomyocyte shortening (max dL/dtS) and lengthening (max
dL/dtL) were also calculated.
Cardiomyocytes were loaded with the Ca
2+ fluorescent dye,
Fura2-AM (25uC, 20 min incubation; Invitrogen, CA, USA).
Myocyte Ca
2+ signals were measured by microfluorimetry
(IonOptix, Milton, MA, USA) [17]. The Fura2 Ca
2+ ratiometric
signal (F360:380 nm) was converted to Ca
2+ concentration based on
in vitro standard curve calibration data employing an Rmin/Rmax
scaling as previously described [18]. The indices used to describe
the Ca
2+ transient (depicted in Figure 1B) were amplitude (nM),
time to peak (ms), time constant of decay (Tau, ms), and duration
(to 90% Ca
2+ transient decay, ms). Transient timing parameters
were referenced to time of stimulus delivery. All indices were
analyzed off-line using IonWizard (IonOptix, Milton, MA, USA)
Figure 1. Cardiomyocyte excitation-contraction coupling analysis. A. Parameters used to describe the myocyte twitch cycle were peak
shortening (PS, mm), peak shortening normalized to diastolic cell length (%PS), area of the shortening phase (AS, mm*ms), area of the lengthening
phase (AL, mm*ms) and area of the total twitch cycle (AT=A S+AL, mm*ms). Area values were determined between baseline and cell length and were
normalized to peak shortening amplitude (AS/PS, AL/PS, AT/PS; mm*ms/mm) in order to compare the relative periods of the shortening and relaxation
periods in different myocytes. B. Parameters used to describe the Ca
2+ transient were amplitude (nM), time to peak (ms), time constant of decay (Tau,
ms) fit from 10% below transient peak, and duration (to 90% Ca
2+ transient decay, ms). Transient timing parameters (time to peak and duration) were
referenced to time of stimulus delivery.
doi:10.1371/journal.pone.0025204.g001
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each myocyte.
Substrate superfusion conditions
To evaluate the effect of fructose on cardiomyocyte excitation-
contraction coupling, myocytes were superfused with one of three
buffer solutions (pH 7.40) defined by sugar substrate availability: a
standard glucose buffer (11 mM glucose, HEPES-Krebs) as
control; a glucose free/glucose metabolic inhibition buffer
(11 mM 2-deoxyglucose, HEPES-Krebs) to deplete ATP and
inhibit contractility; or a fructose buffer (11 mM 2-deoxyglucose
(2 DG), 11 mM fructose, HEPES-Krebs). The latter buffer was
constituted to determine whether fructose can be functionally
utilized as an alternative energy source when glucose metabolism
is inhibited. Simple glucose withdrawal (without 2 DG) was not
sufficient to suppress function in this acute setting (consistent with
occurrence of basal glycogen-derived glucose flux under these
conditions). The fructose concentration (11 mM) was chosen as an
equimolar replacement of glucose to ensure controlled superfusate
conditions (this fructose level would not normally be observed in
vivo). The glucose buffer composition was modeled on standard
formulations used in previous in vitro studies and the glucose
concentration employed is consistent with plasma glucose levels
reported for rodents (generally higher than humans) [19,20,21].
Myocytes were superfused for 2–3 minutes to obtain steady-state,
and measurements of intracellular Ca
2+ and myocyte twitch
kinetics were recorded for a 2 min treatment period for each cell.
Cardiac tissue collection & gene expression analysis
Hearts were excised from anaesthetized Sprague Dawley adult
rats (isofluorane). Adult Sprague Dawley rat cardiomyocytes were
isolated and the cell pellet snap-frozen. Ventricular and cardio-
myocyte RNA was extracted and reverse-transcribed as previously
described [22]. A reverse-transcription negative (i.e. ventricular
RNA processed in the absence of SuperscriptH III RT enzyme)
sample was used as a negative control and a small intestine cDNA
sample was used as a positive control for all PCR analyses.
Relative gene expression levels of cardiac GLUT5 (i.e. Slc2a5;
Accession No. NM_031741) and the housekeeper gene (18S) in
ventricular, cardiomyocyte and small intestine tissue were
determined by real time RT-PCR as previously described [22].
Identification of single melt curve peaks was used to determine
PCR product purity. To confirm the presence of GLUT5 in
cardiac tissues, conventional RT-PCR was performed using
Platinum Taq Polymerase (Invitrogen, CA, USA) with two
consecutive runs of 30 PCR cycles to allow visualization of low
expression genes. Primer sequences were: GLUT5 (Slc2a5; real
time PCR): 59-GAGTGAACGCGATTTACTACTA-39 and 59-
AACCGTGACCATGGTCATGAAC-39; 18S (real time PCR):
59-TCGAGGCCCTGTAATTGGAA-39 and 59-CCCTCCAAT-
GGATCCTCGTT-39 and GLUT5 (Slc2a5; conventional PCR):
59-CAGGTATATCTTCCAACGTGGTC-39 and 59-TAGTAG-
TAAATCGCGTTCACTC-39.
Statistical analyses
Data are expressed as mean (6 standard error) and were
analyzed by 1-way ANOVA and Newman-Keuls post-hoc test,
with p,0.05 considered statistically significant.
Results
Functional in vitro effect of fructose on cardiomyocytes
To establish cardiomyocyte capacity to access and utilize
extracellular fructose in vitro, isolated myocytes were exposed to
HEPES-Krebs superfusate containing fructose as the sole
exogenous energy substrate in the presence of 2-deoxyglucose
(2 DG, 11 mM) to inhibit endogenous glucose metabolism
(hexokinase inhibition [23]). Fructose metabolism bypasses the
2 DG glycolytic inhibition point and proceeds through glycolysis
[7]. Myocyte performance in this fructose-containing buffer was
compared to performance in control glucose (11 mM) and zero
glucose with 2 DG. Diastolic cell length and diastolic Ca
2+ levels
were not different for myocytes in any of these three superfusate
treatment groups (Figure 2A & B). Cell viability was not observed
to be affected by any of the superfusates.
Figure 3A and B depict the representative twitch and Ca
2+
transient profiles under the three substrate-defined cell superfusion
conditions. The extent of myocyte shortening and Ca
2+ transient
amplitude was significantly reduced by 2 DG and the addition of
fructose to the superfusate did not abrogate this effect (Figure 3C
& D). In contrast, the 2 DG-induced increase in the area of the
shortening phase of the twitch (AS/PS) and the delay in the Ca
2+
transient time to peak were normalized by extracellular fructose
(Figure 4A & B; fructose vs. 2 DG twitch: p,0.05; Ca
2+ transient:
p,0.05). Similarly, extracellular fructose normalized the 2 DG-
induced increase in the area of the lengthening phase of the twitch
(AL/PS; Figure 4C), and also suppressed the 2 DG-induced delay
in time to 50% twitch lengthening (data not shown). The time
Figure 2. Baseline twitch and Ca
2+ transient parameters. A. Diastolic cell length. B. Diastolic Ca
2+ levels. Data presented as mean 6 s.e.m.
n=10–28 cells/group.
doi:10.1371/journal.pone.0025204.g002
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2+ transient decay (Tau) was not significantly
modified by addition of 2 DG alone or by fructose with 2 DG
(Figure 4D). The area of the total twitch cycle (AT/PS) was
increased by 2 DG and this increase was reversed by fructose
(Figure 4E), but duration of the Ca
2+ transient was not altered by
2 DG or fructose (Figure 4F). These findings indicate differential
and selective cardiomyocyte twitch and Ca
2+ transient responses to
fructose substitution for glucose in vitro - in the presence of 2 DG,
exogenous fructose can restore the shortening and lengthening
phases of the active cycle, even though suppression of the twitch
peak and Ca
2+ transient amplitude is not relieved.
To investigate the effect of acute fructose on cardiomyocyte
contractility, the maximum rate of shortening and lengthening
were calculated. 2 DG significantly suppressed maximum dL/dtS
and dL/dtL relative to control glucose conditions. The addition of
fructose to the superfusate did not abrogate the 2 DG effect
(Figure 5A and 5B).
To further explore the relationship between twitch and Ca
2+
under the three substrate-defined conditions, correlation analyses
were performed. Figure 6A depicts a significant positive correla-
tion between the area of the total twitch cycle (AT/PS) and the
Ca
2+ transient duration under control glucose conditions. In con-
trast a loss of the relationship between these two parameters was
observed in the 2 DG alone or 2 DG-containing fructose
substituted buffer (Figure 6B & C).
GLUT5 fructose transporter is expressed in myocardial
tissue
To investigate a possible route of cardiomyocyte fructose entry,
real time RT-PCR analysis was utilized to detect GLUT5
expression in adult rat heart homogenate and isolated cardio-
myocytes. Initial fluorescence for amplified GLUT5 PCR
product in rat cardiomyocytes was approximately 20–22 cycles
and rat heart was approximately 24 cycles (Figure 7A), indicating
gene expression at a reproducible, albeit relatively low level.
Initial fluorescence for GLUT5 in rat small intestine tissue was
detected at approximately 15 cycles (Figure 7A). Reverse
transcription ‘negative’ and ‘no template control’ samples did
not amplify in PCR reactions. The melt curve, generated by
progressive temperature increase to 95uC post-PCR amplifica-
tion, revealed a single peak for GLUT5 samples indicating high
PCR product purity (data not shown). Figure 7B presents an
electrophoresis gel image of the GLUT5 conventional RT-PCR
product band located at 481 bp in rat heart and cardiomyocyte
samples. Rat small intestine represents a positive control. No
evidence of the 481 bp product was observed in the negative
control. Cardiac GLUT5 protein assessment could not be
demonstrated using the commercially available antibody (Abcam,
ab41533), as positive control immunoblots (kidney and gut) could
not be generated (possibly indicating low antibody affinity or poor
selectivity).
Figure 3. Effect of acute fructose on twitch and Ca
2+ transient profiles. A. Representative twitch profiles from cardiomyocytes superfused
with glucose, 2 DG, or fructose +2 DG solutions. B. Representative Ca
2+ transient profiles from cardiomyocytes superfused with glucose, 2 DG, or
fructose +2 DG solutions. C. Twitch peak shortening, normalized to diastolic cell length (% PS). D. Ca
2+ transient peak amplitude. Data presented as
mean 6 s.e.m. n=10–28 cells/group. *p,0.05 (1-way ANOVA, Newman-Keuls post-hoc test).
doi:10.1371/journal.pone.0025204.g003
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This investigation provides the first evidence that cardiomyo-
cytes have the capacity to transport and to acutely respond to
exogenous fructose availability. Under specific experimental
conditions of in vitro glucose metabolic inhibition, fructose
abrogated the 2 DG-induced prolongation of twitch timecourse
(i.e. reversal of increased shortening and lengthening timecourse
indices) and Ca
2+ transient (i.e. reversal of increased time to peak
Ca
2+ transient). In a ‘proof-of-principle’ manner, this study
provides functional demonstration that fructose may serve as a
substrate to support cardiomyocyte excitation-contraction cou-
pling in an acute setting. Furthermore, it is established that the
fructose-specific transporter, GLUT5, is expressed in cardiomyo-
cytes and may provide a route of cardiomyocyte fructose entry.
The finding that in the presence of the glucose metabolic
inhibitor 2 DG with glucose deplete buffer, extracellular delivery
of fructose is able to reverse the twitch (both AS/PS and AL/PS)
and Ca
2+ transient (time to peak) prolongation, could be indicative
of an effect of fructose on Ca
2+ release from the sarcoplasmic
Figure 4. Effect of acute fructose on cardiomyocyte shortening and Ca
2+ handling kinetics. A. Area of the shortening phase of the twitch
cycle normalized to peak shortening (AS/PS) B. Time to peak Ca
2+ transient relative to electrical stimulus. C. Area of the lengthening phase of the
twitch cycle normalized to peak shortening (AL/PS). D. Time constant of Ca
2+ transient decay (Tau). E. Area of the total twitch cycle normalized to
peak shortening (AT/PS). F. Duration of the Ca
2+ transient (time from stimulus to 90% Ca
2+ transient decay). Data presented as mean 6 s.e.m. n=10–
28 cells/group. *p,0.05 (1-way ANOVA, Newman-Keuls post-hoc test).
doi:10.1371/journal.pone.0025204.g004
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uptake of Ca
2+ (via activation of the sarcoplasmic reticulum Ca
2+
ATPase (SERCA2)). Under normal conditions SERCA2 has been
estimated to require 15% of ATP produced by the cardiomyocyte
[23,24] and is glycolysis-dependent [25]. A difficulty with this
interpretation is the lack of effect of fructose (or 2 DG) on the
value of the time constant of the Ca
2+ transient decay (Tau,
Figure 4D). It is conventional to assume that altered SERCA2
function is reflected in modified Tau. It may be that in this setting
Tau is a relatively insensitive parameter (indicative of the kinetic of
only a relatively limited portion of the Ca transient decay
timecourse). Altered function of other Ca
2+ transporters may also
be involved in modulating the Ca
2+ transient characteristics. The
Na
+Ca
2+exchanger is indirectly glycolysis-dependent via the
Na
+K
+ATPase which establishes the sarcolemmal Na
+ electro-
chemical gradient. The Na
+K
+ATPase pump is closely associated
with glycolytic enzymes at the sarcolemma and is dependent on
glycolytic ATP [26,27,28]. In the present study, fructose may
provide ATP for this transporter thus increasing the driving force
for Na
+Ca
2+ exchange and promoting Ca
2+ extrusion. This
mechanism is also consistent with the lack of fructose effect
observed on the rate parameters dL/dtS and dL/dtL indicating
that fructose actions are likely occurring during the late phase of
the shortening and lengthening cycle.
Interestingly we find that that the expected positive correlation
between twitch cycle length and transient duration, prominent in
the control glucose superfused myocytes, is absent in the 2 DG
treated myocytes (Figure 6B & C). This suggests that in the glucose
deficient state, the mechanisms which modify the combined
shortening and lengthening phases of the cycle are different to the
Ca
2+ handling processes which dominate in the very late phase of
relaxation. More extensive pharmacological investigation is re-
quired to establish precisely how fructose-derived ATP may interact
with Ca
2+ handling proteins to contribute to the Ca
2+ and twitch
modifications observed, at different phases during the contractile
cycle.Although fructose had markedeffectson the timecourse ofthe
twitch and Ca
2+ transient, the 2 DG-induced decrease in the extent
of myocyte shortening and the Ca
2+ transient amplitude was not
Figure 5. Effect of fructose on cardiomyocyte contractility. A. Maximum rate of cardiomyocyte shortening (max dL/dtS). B. Maximum rate of
cardiomyocyte lengthening (max dL/dtL). Data presented as mean 6 s.e.m. n=10–28 cells/group. *p,0.05 (1-way ANOVA, Newman-Keuls post-hoc
test).
doi:10.1371/journal.pone.0025204.g005
Figure 6. Altered myocyte shortening-Ca
2+ relationship. A. Correlation of area of the total twitch cycle normalized to peak shortening (AT/PS)
and Ca
2+ transient duration for myocytes superfused under control glucose conditions (R
2=0.416; *p,0.05). B. Correlation of area of the total twitch
cycle normalized to peak shortening (AT/PS) and Ca
2+ transient duration for myocytes superfused under 2 DG conditions (R
2=0.028; p=ns). C.
Correlation of area of the total twitch cycle normalized to peak shortening (AT/PS) and Ca
2+ transient duration for myocytes superfused under
fructose +2 DG conditions (R
2=0.002; p=ns).
doi:10.1371/journal.pone.0025204.g006
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on cardiomyocyte excitation-contraction coupling is not clear. An
effect of 2 DG per se on sarcoplasmic reticulum Ca
2+ storage
capacity could be implicated, but at present there is no evidence
from other sources to evaluate this proposition.
The in vitro manoeuvre (with relatively high fructose) in the
present study demonstrates that fructose is able to modify
cardiomyocyte contraction and relaxation timecourse when
applied acutely. The manner in which sustained high fructose
exposure remodels cardiomyocyte excitation-contraction coupling
in vivo may be qualitatively different - and potentially detrimental.
In the present study cardiomyocyte viability was not affected by
the acute fructose superfusion, but it has been recently reported
that chronic dietary fructose exposure is associated with activation
of myocardial autophagic programmed cell death signaling [29].
Long-term impacts of fructose-mediated phosphofructokinase
bypass on cardiomyocyte metabolism may be ultimately detri-
mental to myocardial contractility involving oxidative stress and
glycosylation-mediated dysfunction [17]. The high reactivity of
fructose and its metabolites (relative to glucose) may contribute to
the formation of intracellular advanced glycation end-products
(AGEs) and intracellular protein modifications [30]. The hexos-
amine biosynthesis pathway mediates O-linked N-acetyl-glucos-
amine (O-GlcNAc) regulation of key proteins in cardiomyocytes
driven by fructose-6-phosphate (a metabolite of glycolysis) [31,32].
Although hepatocyte fructose conversion to fructose-6-phosphate
is well established [7], in cardiomyocytes there has not previously
been a rationale to prompt evaluation of fructose contribution to
cardiomyocyte O-GlcNAcylation. The evidence of cardiomyocyte
fructose access presented in this study, provides a basis to pursue
further investigations in this field.
The novel finding that the fructose-specific transporter, GLUT5,
is expressed in rodent cardiomyocytes suggests that cardiac fructose
metabolism may be of functional importance, a possibility not
previously identified. Earlier attempts to detect cardiac GLUT5 by
northern blot were unsuccessful [33,34], and no data have been
previously presented to identify GLUT5 protein in the heart [35].
Using an alternative approach, involving both real time and
conventional PCR, we have clearly demonstrated cardiomyocyte
GLUT5 gene expression. Interestingly, the GLUT5 expression
measured in cardiomyocytes is higher than in the heart homoge-
nate, suggesting that the average GLUT5 expression is more
prominent in cardiomyocytes than other cell types. Earlier failure to
detect cardiac GLUT5 by Northern blot suggests this technique
may not be sufficiently sensitive to detect this gene expressed at a
low level. Fructose uptake by transporters which mediate fructose
and glucose entry competitively (e.g. GLUT11 and GLUT12
[12,13]) wouldbe unlikely tooccurinvivo.Incontrast,GLUT5 has a
low affinity for glucose. In the in vitro conditions of the present study,
it cannot be determined whether fructose cardiomyocyte entry is via
GLUT5, but these expression data provide evidence of cardiomy-
ocyte capacity to transport fructose under in vivo conditions of
relatively high glucose. Future investigation involving cardiomyo-
cyte GLUT5 knockdown will elucidatethe role of this transporter in
cardiomyocyte fructose metabolism.
In conclusion, this is the first study to demonstrate an acute
influence of fructose on cardiomyocyte excitation-contraction
coupling. The findings indicate cardiomyocyte capacity to
transport and functionally utilize exogenously supplied fructose.
Further research directed towards characterizing myocardial
fructose metabolism and evaluating the long-term modulation of
myocardial function by elevated endogenous fructose is now
warranted. Dietary fructose intake is increasing and a role for
direct fructose action in the development of insulin resistant
cardiomyopathy requires investigation.
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